West Pharmaceutical CEO Plans Exit after 11 Years, Succession Process Underway

Core Insights - West Pharmaceutical Services, Inc. (NYSE:WST) is recognized as part of the Dividend Kings and Aristocrats List, indicating its strong dividend performance [1] Leadership Transition - CEO Eric Green plans to retire after an 11-year tenure, with the transition expected in the second half of 2026 [2] - Green has been with the company since 2015 and became board chair in 2022, stating that it is time for new leadership [3] - Under Green's leadership, the company more than doubled its sales and achieved a total shareholder return of approximately 350% [3] Business Operations - West Pharmaceutical manufactures components and devices for delivering injectable drugs, including treatments for diabetes and obesity [4] - The company anticipates continued growth in demand for GLP-1 therapies in 2026, although at a slower rate than in 2025 [4] - West operates as a global manufacturer focused on integrated containment and delivery systems for injectable drugs and healthcare products [4]